Question 1
In your JDD podcast interview, you mentioned that about 50-60% of your patients with LPP respond to naltrexone. Have you seen any similarities between these responders that could help dermatologists identify which patients would be good candidates for naltrexone as an adjunctive therapy?
Answer
"No I have not seen any similarities. The response is unpredictable."
Quest … Continue reading "GW Resident Segment – December Edition with Dr. Shapiro"
Human fibroblasts are a versatile source of optimal growth factors that provide approaches to repair skin in Upregulation of Extracellular Matrix Genes Corroborates Clinical Efficacy of Human Fibroblast-Derived Growth Factors in Skin Rejuvenation
By working from a CD8+ T cell line, it should be possible to identify and patent products capable of treating infectious diseases, antigen- … 
Catch up on your JDD reading with highlights from the August issue, Special Focus: Psoriasis.
Strober, Bagel, and Lebwohl et al present Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study READ NOW
The Static Physician’s Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Ps … Continue reading "JDD August Highlights – Special Focus: Psoriasis"
Go superpotent or go home. The utility and safety of Class 1 topical steroids.
Dr. Tina Bhutani and Dr. Adam Friedman
In this edition of the JDD Podcast, Ask the Investigator, host Dr. Adam Friedman digs deep with UCSF Assistant Professor of Dermatology Dr. Tina Bhutani to powerlift the most up to date safety data on Class 1 superpotent topical steroids from her study entitled "Update on the … Continue reading "August JDD Podcast: Go Superpotent or Go Home"
